Work

PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma

Year: 2025

Type: article

Study design: Study Protocol

Source: Future Oncology

DOI: 10.1080/14796694.2025.2577625

Authors: Diao Kong, Yongcheng Tang, Yongjie Zhou, Jin Zhou, Chuan Li, Tianfu Wen, Wei Peng

Institutions: Sichuan University, West China Hospital of Sichuan University, Southwest Medical University, Affiliated Hospital of Southwest Medical University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Natural Science Foundation of Sichuan Province

Award: G3795532832

OpenAlex ID: W4415400369

FWCI:

Cites: 32

Cited by:

Related to: